AbbVie 4Q Revenues: $14.3 billion (-5%)  4Q Earnings: $824 million (earnings were $2.5 billion 4Q22) FY Revenues: $54.3 billion (-6%) FY Earnings: $4.9 billion (earnings were $11.8 billion FY22) Comments: Global immunology portfolio revenues were down 12% in the quarter to $6.95 billion, due to Humira biosimilar competition. Global Humira sales were $3.3 billion, down 41%. Global Skyrizi revenues were $2.4 billion, up 52%. Global Rinvoq revenues were $1.3 billion, up 63%. Oncology portfolio...